No Data
No Data
Xianju Pharmaceutical (002332): Revenue performance in '23 is under pressure, 24Q1 returns to positive growth
Core idea In '23, the company's API sector was affected by increased competition in the industry market. The pharmaceutical side was affected by collection, annual revenue fell 5.9% year on year, net profit after deducting non-return mother fell 12.1% year on year, and revenue profit was under pressure. 24Q1 Receipt
Xianju Pharmaceutical (002332) Review Report: The company's performance reached an inflection point. Q1 performance in '24 exceeded expectations
Company announcement 2023 annual report: In 2023, the company achieved operating income of 4.123 billion yuan (yoy -5.85%), net profit to mother 563 million yuan (yoy -24.86%), deducting net profit of non-return to mother 5.
Xianju Pharmaceutical (002332): 2023 results are under pressure, 24Q1 revenue returns to positive growth
Incident: The company released its 2023 annual report and 2014 quarterly report. In 2023, the company achieved revenue of 4.123 billion yuan (-5.85%), net profit to mother and deducted non-net profit of 563 million yuan (-24.86%), 5
Xianju Pharmaceutical (002332): The impact of mining has passed, 1Q24 results have begun positive growth
Performance is under pressure due to the influence of collection in '23. It is expected to usher in a clear inflection point in '24. The company published its annual report for '23 and its quarterly report for '24, with revenue of 4.12 billion yuan (-5.9% yoy) in '23, and net profit of 5 to mother
Xianju Pharmaceutical (002332.SZ): Net profit of 151 million yuan in the first quarter increased 13.53% year-on-year
Gelonghui, April 24, 丨 Xianju Pharmaceutical (002332.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,038 million yuan, up 8.42% year on year; net profit attributable to shareholders of listed companies was 151 million yuan, up 13.53% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 145 million yuan, up 9.83% year on year; basic earnings per share were 0.15 yuan.
Express News | The research team of the Price and Cost Research Center of the National Development and Reform Commission visited Xianju Pharmaceutical for research
No Data